Can you specify the new chemical components in apotex's ruxolitinib formulation?

I don’t have access to Apotex’s internal formulation records. If there were changes to their ruxolitinib product, the only definitive source would be the official regulatory labeling (and any corresponding Summary of Product Characteristics or regulatory filing) for the country/market in question. Those documents list the exact inactive ingredients (excipients) and would indicate any new components.

What you can do to find the exact information:
- Tell me the country or regulatory region (e.g., US, Canada, EU) and, if you have it, the product code or DIN/ANDA number.
- Look up the product label:
- US: Search DailyMed for “ruxolitinib” and the Apotex product name to see the “Inactive ingredients” list.
- Canada: Check Health Canada’s Drug Product Database or the product monograph for Apotex’s ruxolitinib.
- EU: Check the European Medicines Agency (EMEA/EPAR) or the national competent authority for the specific Apotex product.
- If you have a photo or a text snippet of the label or SmPC, share it and I’ll help parse the excipients and highlight any new components.

If you’d like, I can guide you through a step-by-step search in the relevant database or help interpret the labels once you provide the country and product code. Also, I can give you a general sense of which excipients are commonly used in tablet formulations of ruxolitinib (though this won’t confirm Apotex’s exact formulation).